Kenny77
2021-12-20
Please like
PolarityTE Shares Advance 10% After Submitting Response to FDA
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693622811,"tweetId":"693622811","gmtCreate":1640015329554,"gmtModify":1640015330237,"author":{"id":3553679778150469,"idStr":"3553679778150469","authorId":3553679778150469,"authorIdStr":"3553679778150469","name":"Kenny77","avatar":"https://static.tigerbbs.com/77c5e512c4b7983d3f3075d8ec4c2f2d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":64,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like</p></body></html>","htmlText":"<html><head></head><body><p>Please like</p></body></html>","text":"Please like","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693622811","repostId":1102069847,"repostType":4,"repost":{"id":"1102069847","kind":"news","pubTimestamp":1640007976,"share":"https://www.laohu8.com/m/news/1102069847?lang=&edition=full","pubTime":"2021-12-20 21:46","market":"us","language":"en","title":"PolarityTE Shares Advance 10% After Submitting Response to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1102069847","media":"Marketwatch","summary":"PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a com","content":"<p>PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new drug application for SkinTE with a proposed indication for chronic cutaneous ulcers.</p>\n<p>The primary hold correspondence from the FDA related to certain chemistry, manufacturing and control items, including the assay to demonstrate the potency of SkinTE, the company said.</p>\n<p>In premarket trading, the stock was 10% higher after ending Friday at 39 cents, down more than 40% since the end of last year.</p>\n<p>PolarityTE said that under FDA's standard practices and regulations, if the regulator agrees that the company's response is complete then a decision should be communicated within 30 days, subject to potential delays or other unforeseen circumstances.</p>\n<p>\"We believe that our response is robust and compelling in terms of addressing the issues raised by the FDA,\" Chief Executive Officer and President Richard Hague said.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolarityTE Shares Advance 10% After Submitting Response to FDA </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolarityTE Shares Advance 10% After Submitting Response to FDA \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 21:46 GMT+8 <a href=https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new ...</p>\n\n<a href=\"https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PTE":"PolarityTE, Inc."},"source_url":"https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1102069847","content_text":"PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new drug application for SkinTE with a proposed indication for chronic cutaneous ulcers.\nThe primary hold correspondence from the FDA related to certain chemistry, manufacturing and control items, including the assay to demonstrate the potency of SkinTE, the company said.\nIn premarket trading, the stock was 10% higher after ending Friday at 39 cents, down more than 40% since the end of last year.\nPolarityTE said that under FDA's standard practices and regulations, if the regulator agrees that the company's response is complete then a decision should be communicated within 30 days, subject to potential delays or other unforeseen circumstances.\n\"We believe that our response is robust and compelling in terms of addressing the issues raised by the FDA,\" Chief Executive Officer and President Richard Hague said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":949,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693622811"}
精彩评论